Compare Amgen, Inc. (AMGN) vs Levi Strauss & Co. (LEVI) Price & Performance

AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.

The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.

Levi Strauss (LEVI) trades at $24.31, up 2.02% today, showing strong fundamental performance with consistent earnings beats and robust profitability metrics. The company recently raised its dividend and full-year guidance following Q2 2026 results, demonstrating confidence in its digital strategy and direct-to-consumer growth. Technical indicators show mixed signals with bearish overall momentum but strong support at $23. Analyst consensus remains overwhelmingly bullish with an 83% buy rating and $28 price target, representing 15% upside potential.

LEVI presents a compelling investment case with strong fundamentals, consistent earnings outperformance, and positive business momentum. Key opportunities include the successful digital transformation, expanding direct-to-consumer sales, and dividend growth. Risks include tariff pressures, foreign exchange volatility, and competitive retail landscape. The stock offers attractive valuation with 15% upside to consensus target, supported by strong cash flow generation and improving balance sheet metrics.